Abcam and Wuxi Diagnostics Expand Partnership into Companion Diagnostics
UK-headquartered Abcam plc. and China-based Wuxi Diagnostics have expanded their partnership to dive deep into...
Cancer
Ascentage Pharma’s APG-2575 Shows Promising Results in Global Phase II Study
Suzhou-based Ascentage Pharma (HKG: 6855) unveiled preliminary data from the global Phase II clinical study...
ImmuneOnco’s IMM2520 Receives FDA Clinical Trial Approval
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced receiving clinical trial approval from the US FDA for...
Treadwell Therapeutics Presents PLK4 Inhibitor Data at ASH Annual Meeting
China-based Treadwell Therapeutics presented results of the company’s CFI-400945 program, a first-in-class inhibitor of Polo-like...
Asieris Pharmaceuticals Enrolls First Patient in Phase II Study for APL-1202
China-based Asieris Pharmaceuticals (SHA: 688176) announced the first patient enrollment in a Phase II clinical...
Angel Pharmaceuticals Presents CPI-818 Data at ASH 2022 Annual Meeting
China-based Angel Pharmaceuticals Ltd announced the latest results of the global Phase I/Ib clinical study...
Wuhan YZY Biopharma Files for IPO on Hong Kong Stock Exchange
China-based Wuhan YZY Biopharma Co., Ltd, a biopharmaceutical company focused on targeted cancer drugs and...
JW Therapeutics Presents Carteyva Data at ASH Annual Meeting
China-based JW Therapeutics (HKG: 2126) presented the latest clinical data on Carteyva (relmacabtagene autoleucel injection)...
Dizal Pharma Presents Golidocitinib Data at ASH Annual Meeting
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented the latest clinical data on golidocitinib (DZD4205)...
Sino Biopharmaceutical’s ATR Kinase Inhibitor TCC1727 Accepted for FDA Review
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced the acceptance for review of its Investigational New...
Medbanks Set for IPO on Hong Kong Stock Exchange
Sipai Health Technology Co., Ltd, also known as Medbanks, is set to make an initial...
Alphamab Oncology Updates Clinical Studies for KN046 and KN026 at SABCS 2022
China-based Alphamab Oncology (HKG: 9966) updated the clinical studies for its KN046 and KN026 at...
Roche and Zhongshan Hospital Collaborate on Clinical Studies and Innovation Center
Swiss giant Roche’s (SWX: ROG) China unit and Roche Diagnostics’ China unit entered into a...
ASH 2022: China Biotechs Showcase Latest Clinical Trial Results
The American Society of Hematology (ASH) 2022 annual meeting, held online and offline in New...
RemeGen’s RC118 Receives Orphan Drug Designations for Gastric and Pancreatic Cancers
China-based RemeGen Ltd announced that its antibody drug conjugate (ADC) drug candidate RC118 has obtained...
Innovent Biologics Presents Clinical Study Results at ESMO-IO 2022
China-based Innovent Biologics Inc. (HKG: 1801) announced the presentation of two clinical studies at the...
Phanes Therapeutics and BeiGene Partner on Phase I Study of PT199
Sino-US biotech Phanes Therapeutics Inc. announced a clinical study cooperation and supply agreement with China-based...
Harbour BioMed Concludes Phase I Study for HBM4003 in Advanced Melanoma
Harbour BioMed (HBM; HKG: 2142), a biotech operating out of the United States, the Netherlands,...
Harbour BioMed’s Nona Biosciences Licenses Antibody Platform to Kelun-Biotech
Harbour BioMed (HKG: 2142), a biotech operating out of the Netherlands, the United States, and...
Jacobio’s KRAS G12C Inhibitor JAB-21822 Receives Breakthrough Therapy Designation
The Center for Drug Evaluation (CDE) website indicates that China-based Jacobio Pharmaceuticals Group Co., Ltd’s...